$PBH
Prestige Consumer Healthcare Inc. Stock $pbh

$pbh Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000129594723000026 Filed on August 03, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$286.3M	$279.3M
YoY Change	-1.02%	0.81%
Cost Of Revenue	$126.3M	$124.6M
YoY Change	-1.53%	6.58%
Gross Profit	$160.0M	$154.7M
YoY Change	-0.61%	-3.4%
Gross Profit Margin	55.89%	55.38%
Selling, General & Admin	$66.10M	$63.92M
YoY Change	-5.92%	-4.12%
% of Gross Profit	41.31%	41.32%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$7.643M	$7.543M
YoY Change	20.02%	-10.03%
% of Gross Profit	4.78%	4.88%
Operating Expenses	$71.77M	$69.48M
YoY Change	-6.34%	-4.96%
Operating Profit	$88.25M	$85.19M
YoY Change	4.58%	-2.09%
Interest Expense	-$17.61M	-$17.72M
YoY Change	3.69%	15.87%
% of Operating Profit	-19.95%	-20.8%
Other Income/Expense, Net	-$229.0K	$1.238M
YoY Change	-71.8%	-250.06%
Pretax Income	$70.42M	$68.71M
YoY Change	5.74%	-3.08%
Income Tax	$16.86M	$15.44M
% Of Pretax Income	23.94%	22.47%
Net Earnings	$53.56M	$53.28M
YoY Change	4.97%	-3.61%
Net Earnings / Revenue	18.71%	19.07%
Basic Earnings Per Share	$1.08	$1.07
Diluted Earnings Per Share	$1.07	$1.06
COMMON SHARES
Basic Shares Outstanding	49.54M shares	49.69M shares
Diluted Shares Outstanding	50.08M shares	50.20M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.07M	$54.58M
YoY Change	41.53%	52.16%
Cash & Equivalents	$60.07M	$54.58M
Short-Term Investments
Other Short-Term Assets	$8.392M	$9.379M
YoY Change	8.79%	-1.55%
Inventory	$161.3M	$169.8M
Prepaid Expenses
Receivables	$158.5M	$158.0M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$388.2M	$391.8M
YoY Change	15.31%	20.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$70.70M	$69.98M
YoY Change	1.08%	-0.59%
Goodwill	$526.9M	$527.5M
YoY Change	-8.46%	-8.55%
Intangibles	$2.328B	$2.336B
YoY Change	-12.83%	-12.92%
Long-Term Investments
YoY Change
Other Assets	$3.862M	$3.267M
YoY Change	49.86%	19.1%
Total Long-Term Assets	$2.945B	$2.954B
YoY Change	-11.89%	-12.03%
TOTAL ASSETS
Total Short-Term Assets	$388.2M	$391.8M
Total Long-Term Assets	$2.945B	$2.954B
Total Assets	$3.333B	$3.346B
YoY Change	-9.4%	-9.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$44.38M	$57.86M
YoY Change	-21.02%	-0.43%
Accrued Expenses	$74.29M	$76.79M
YoY Change	-8.13%	-4.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.876M	$2.855M
YoY Change	2.97%	2.99%
Total Short-Term Liabilities	$129.7M	$147.3M
YoY Change	-14.84%	-5.2%
LONG-TERM LIABILITIES
Long-Term Debt	$1.275B	$1.330B
YoY Change	-12.37%	-10.74%
Other Long-Term Liabilities	$8.896M	$8.183M
YoY Change	0.21%	-8.24%
Total Long-Term Liabilities	$1.284B	$1.338B
YoY Change	-12.29%	-10.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$129.7M	$147.3M
Total Long-Term Liabilities	$1.284B	$1.338B
Total Liabilities	$1.797B	$1.865B
YoY Change	-12.71%	-11.07%
SHAREHOLDERS EQUITY
Retained Earnings	$1.239B	$1.185B
YoY Change	-6.19%	-6.64%
Common Stock	$552.0K	$552.0K
YoY Change	0.91%	0.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.536B	$1.480B
YoY Change
Total Liabilities & Shareholders Equity	$3.333B	$3.346B
YoY Change	-9.4%	-9.14%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	$53.56M	$53.28M
YoY Change	4.97%	-3.61%
Depreciation, Depletion And Amortization	$7.643M	$7.543M
YoY Change	20.02%	-10.03%
Cash From Operating Activities	$62.46M	$48.09M
YoY Change	8.55%	-17.44%
INVESTING ACTIVITIES
Capital Expenditures	$2.934M	$1.477M
YoY Change	-223.48%	41.07%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$3.800M
YoY Change
Cash From Investing Activities	-$2.934M	$2.323M
YoY Change	23.48%	-321.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-53.55M	-$54.18M
YoY Change	11.66%	14.36%
NET CHANGE
Cash From Operating Activities	62.46M	$48.09M
Cash From Investing Activities	-2.934M	$2.323M
Cash From Financing Activities	-53.55M	-$54.18M
Net Change In Cash	5.977M	-$3.909M
YoY Change	-17.08%	-145.01%
FREE CASH FLOW
Cash From Operating Activities	$62.46M	$48.09M
Capital Expenditures	$2.934M	$1.477M
Free Cash Flow	$59.53M	$46.61M
YoY Change	-0.65%	-18.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-17719000	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-15292000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022Q2	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	790000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-646000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-10309000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	52630000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	44963000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54580000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58489000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	24928000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	20205000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	157950000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	167016000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	169849000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	162121000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9379000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4117000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	391758000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	391743000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	69979000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	70412000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13443000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14923000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3535000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	4200000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	527458000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	527553000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2336137000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2341893000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3267000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3005000	usd
CY2023Q2	us-gaap	Assets Assets	3345577000	usd
CY2023Q1	us-gaap	Assets Assets	3353729000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	57861000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	62743000	usd
CY2023Q2	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	15188000	usd
CY2023Q1	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	15688000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6600000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6926000	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2855000	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2834000	usd
CY2023Q2	pbh	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	64767000	usd
CY2023Q1	pbh	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	72524000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	147271000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	160715000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	1316711000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	1345788000	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	383955000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	380434000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8217000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9876000	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	945000	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1667000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8183000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8165000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	1865282000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1906645000	usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55220000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54857000	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	552000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	548000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	546526000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	535356000	usd
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	5680000	shares
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	5165000	shares
CY2023Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	219707000	usd
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	189114000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-32210000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31564000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1185134000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1131858000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1480295000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1447084000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3345577000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3353729000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1447084000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4146000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7028000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	30593000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	53276000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-646000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1480295000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1577611000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3857000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1489000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	43177000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	55272000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-10309000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1584743000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	53276000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	55272000	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7543000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8384000	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-13000	usd
CY2023Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4272000	usd
CY2022Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1213000	usd
CY2023Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	983000	usd
CY2022Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	828000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	4146000	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	3857000	usd
CY2023Q2	pbh	Additions To Operating Lease Right Of Use Assets AdditionsToOperatingLeaseRightOfUseAssets	1244000	usd
CY2022Q2	pbh	Additions To Operating Lease Right Of Use Assets AdditionsToOperatingLeaseRightOfUseAssets	1493000	usd
CY2023Q2	us-gaap	Other Noncash Expense OtherNoncashExpense	0	usd
CY2022Q2	us-gaap	Other Noncash Expense OtherNoncashExpense	446000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5632000	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7079000	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7711000	usd
CY2022Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14415000	usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5181000	usd
CY2022Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3227000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5599000	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2542000	usd
CY2023Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8519000	usd
CY2022Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	10524000	usd
CY2023Q2	pbh	Increase Decrease In Operating Leases Liabilities IncreaseDecreaseInOperatingLeasesLiabilities	-1745000	usd
CY2022Q2	pbh	Increase Decrease In Operating Leases Liabilities IncreaseDecreaseInOperatingLeasesLiabilities	-1602000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	254000	usd
CY2022Q2	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	2000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	48087000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	58247000	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1477000	usd
CY2022Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1047000	usd
CY2023Q2	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-3800000	usd
CY2022Q2	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2323000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1047000	usd
CY2023Q2	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	30000000	usd
CY2022Q2	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	15000000	usd
CY2023Q2	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2022Q2	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	20000000	usd
CY2023Q2	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2022Q2	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	10000000	usd
CY2023Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	699000	usd
CY2022Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	686000	usd
CY2023Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7028000	usd
CY2022Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1489000	usd
CY2023Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5508000	usd
CY2022Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5450000	usd
CY2023Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	25000000	usd
CY2022Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	37727000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-54179000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-47374000	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-140000	usd
CY2022Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1142000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3909000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8684000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58489000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27185000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54580000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	35869000	usd
CY2023Q2	us-gaap	Interest Paid Net InterestPaidNet	17582000	usd
CY2022Q2	us-gaap	Interest Paid Net InterestPaidNet	3562000	usd
CY2023Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	11964000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	169849000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	162121000	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4900000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	5800000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2336137000	usd
CY2022Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid	1799000	usd
CY2023Q2	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions.
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	22671000	usd
CY2023Q1	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	20634000	usd
CY2023Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	291000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	220000	usd
CY2023Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	146887000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	141267000	usd
CY2023Q1	us-gaap	Goodwill Gross GoodwillGross	741656000	usd
CY2023Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	214103000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	527553000	usd
CY2023Q2	us-gaap	Goodwill Transfers GoodwillTransfers	0	usd
CY2023Q2	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-95000	usd
CY2023Q2	us-gaap	Goodwill Gross GoodwillGross	741561000	usd
CY2023Q2	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	214103000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	527458000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	48800000	usd
CY2023Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	2580020000	usd
CY2023Q2	pbh	Intangible Assets Translation Adjustments Gain Loss IntangibleAssetsTranslationAdjustmentsGainLoss	-816000	usd
CY2023Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	2579204000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	238127000	usd
CY2023Q2	pbh	Finite Lived Intangible Assets Accumulated Amortization Translation Adjustments Gain Loss FiniteLivedIntangibleAssetsAccumulatedAmortizationTranslationAdjustmentsGainLoss	13000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	243067000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5000000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5600000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	15433000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	18906000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	16956000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	15363000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	13017000	usd
CY2023Q2	pbh	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	88231000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	167906000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	321400000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	665000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	665000	usd
CY2023Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	30000	usd
CY2022Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	50000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1624000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1634000	usd
CY2023Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	33000	usd
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	34000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	16456000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	11999000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	18808000	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	14382000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	5265000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	2191000	usd
CY2023Q2	pbh	Operating And Finance Lease Liability Payments Remainder Of Fiscal Year OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	7456000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4743000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1509000	usd
CY2023Q2	pbh	Operating And Finance Lease Liability Payments Due Year One OperatingAndFinanceLeaseLiabilityPaymentsDueYearOne	6252000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2260000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	96000	usd
CY2023Q2	pbh	Operating And Finance Lease Liability Payments Due Year Two OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo	2356000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1889000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	80000	usd
CY2023Q2	pbh	Operating And Finance Lease Liability Payments Due Year Three OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree	1969000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1436000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q2	pbh	Operating And Finance Lease Liability Payments Due Year Four OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour	1436000	usd
CY2023Q2	pbh	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	264000	usd
CY2023Q2	pbh	Finance Lease Liability To Be Paid Due After Year Four FinanceLeaseLiabilityToBePaidDueAfterYearFour	0	usd
CY2023Q2	pbh	Operating And Finance Lease Liability Payments Due After Year Four OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour	264000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15857000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	3876000	usd
CY2023Q2	pbh	Operating And Finance Lease Liability Payment Due OperatingAndFinanceLeaseLiabilityPaymentDue	19733000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1040000	usd
CY2023Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	76000	usd
CY2023Q2	pbh	Operating And Finance Lease Liability Undiscounted Excess Amount OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount	1116000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	14817000	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	3800000	usd
CY2023Q2	pbh	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	18617000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M24D
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M12D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0351
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0295
CY2023Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	33143000	usd
CY2023Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	30471000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5807000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14292000	usd
CY2023Q2	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1958000	usd
CY2023Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1767000	usd
CY2023Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	9764000	usd
CY2023Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	10645000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4056000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4254000	usd
CY2023Q2	pbh	Accrued Production Costs Current AccruedProductionCostsCurrent	4593000	usd
CY2023Q1	pbh	Accrued Production Costs Current AccruedProductionCostsCurrent	5700000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5446000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5395000	usd
CY2023Q2	pbh	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	64767000	usd
CY2023Q1	pbh	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	72524000	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1330000000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1360000000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	13289000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	14212000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	1316711000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	1345788000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	400000000	usd
CY2023Q2	pbh	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	930000000	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1330000000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	pbh	Voting Rights Number Of Votes Per Common Share Owned VotingRightsNumberOfVotesPerCommonShareOwned	1	vote
CY2023Q2	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2023Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	25000000	usd
CY2023	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	0	usd
CY2023Q2	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	0	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	53276000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	55272000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49767000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50264000	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	429000	shares
CY2022Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	466000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50196000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50730000	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.07
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.10
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.06
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.09
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4146000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3857000	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	406000	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	537000	usd
CY2023Q2	pbh	Share Based Compensation Arrangement By Share Based Payment Award Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedInPeriodTotalFairValue	11226000	usd
CY2022Q2	pbh	Share Based Compensation Arrangement By Share Based Payment Award Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedInPeriodTotalFairValue	10225000	usd
CY2023Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7028000	usd
CY2022Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1489000	usd
CY2023Q2	pbh	Effective Income Tax Rate Reconciliation Deduction Restricted Stock Issuances And Stock Options Amount EffectiveIncomeTaxRateReconciliationDeductionRestrictedStockIssuancesAndStockOptionsAmount	876000	usd
CY2022Q2	pbh	Effective Income Tax Rate Reconciliation Deduction Restricted Stock Issuances And Stock Options Amount EffectiveIncomeTaxRateReconciliationDeductionRestrictedStockIssuancesAndStockOptionsAmount	2895000	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4600000	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1900000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1100900	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.62
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	197600	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	54.48
CY2022Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	39100	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	38.04
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1259400	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	42.88
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	20052000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	827000.0	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	39.98
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M12D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	15567000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1081000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	43.96
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	128100	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	61.73
CY2023Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	172900	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	40.64
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	19300	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	54.86
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1700	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	54.47
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1015200	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	46.54
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13369000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	700100	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	42.70
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11714000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3200000	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.225
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.220
CY2023Q2	pbh	Number Of Third Party Manufacturers NumberOfThirdPartyManufacturers	135	manufacturer
CY2022Q2	pbh	Number Of Third Party Manufacturers NumberOfThirdPartyManufacturers	129	manufacturer
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	279309000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	124636000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	154673000	usd
CY2023Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	36231000	usd
CY2023Q2	pbh	Contribution Margin ContributionMargin	118442000	usd
CY2023Q2	pbh	General And Administrative And Depreciation And Amortization Expense GeneralAndAdministrativeAndDepreciationAndAmortizationExpense	33248000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	85194000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	277059000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	116940000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	160119000	usd
CY2022Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	39951000	usd
CY2022Q2	pbh	Contribution Margin ContributionMargin	120168000	usd
CY2022Q2	pbh	General And Administrative And Depreciation And Amortization Expense GeneralAndAdministrativeAndDepreciationAndAmortizationExpense	33154000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	87014000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	279309000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	277059000	usd

Files In Submission

Name	View Source	Status
0001295947-23-000026-index-headers.html	Edgar Link	pending
0001295947-23-000026-index.html	Edgar Link	pending
0001295947-23-000026.txt	Edgar Link	pending
0001295947-23-000026-xbrl.zip	Edgar Link	pending
exhibit3112023-06x30.htm	Edgar Link	pending
exhibit3122023-06x30.htm	Edgar Link	pending
exhibit3212023-06x30.htm	Edgar Link	pending
exhibit3222023-06x30.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbh-20230630.htm	Edgar Link	pending
pbh-20230630.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pbh-20230630_g1.jpg	Edgar Link	pending
prestige-amendmentno7tot.htm	Edgar Link	pending
prestige-amendmentno7tot001.jpg	Edgar Link	pending
prestige-amendmentno7tot002.jpg	Edgar Link	pending
prestige-amendmentno7tot003.jpg	Edgar Link	pending
prestige-amendmentno7tot004.jpg	Edgar Link	pending
prestige-amendmentno7tot005.jpg	Edgar Link	pending
prestige-amendmentno7tot006.jpg	Edgar Link	pending
prestige-amendmentno7tot007.jpg	Edgar Link	pending
prestige-amendmentno7tot008.jpg	Edgar Link	pending
prestige-amendmentno7tot009.jpg	Edgar Link	pending
prestige-amendmentno7tot010.jpg	Edgar Link	pending
prestige-amendmentno7tot011.jpg	Edgar Link	pending
prestige-amendmentno7tot012.jpg	Edgar Link	pending
prestige-amendmentno7tot013.jpg	Edgar Link	pending
prestige-amendmentno7tot014.jpg	Edgar Link	pending
prestige-amendmentno7tot015.jpg	Edgar Link	pending
prestige-amendmentno7tot016.jpg	Edgar Link	pending
prestige-amendmentno7tot017.jpg	Edgar Link	pending
prestige-amendmentno7tot018.jpg	Edgar Link	pending
prestige-amendmentno7tot019.jpg	Edgar Link	pending
prestige-amendmentno7tot020.jpg	Edgar Link	pending
prestige-amendmentno7tot021.jpg	Edgar Link	pending
prestige-amendmentno7tot022.jpg	Edgar Link	pending
prestige-amendmentno7tot023.jpg	Edgar Link	pending
prestige-amendmentno7tot024.jpg	Edgar Link	pending
prestige-amendmentno7tot025.jpg	Edgar Link	pending
prestige-amendmentno7tot026.jpg	Edgar Link	pending
prestige-amendmentno7tot027.jpg	Edgar Link	pending
prestige-amendmentno7tot028.jpg	Edgar Link	pending
prestige-amendmentno7tot029.jpg	Edgar Link	pending
prestige-amendmentno7tot030.jpg	Edgar Link	pending
prestige-amendmentno7tot031.jpg	Edgar Link	pending
prestige-amendmentno7tot032.jpg	Edgar Link	pending
prestige-amendmentno7tot033.jpg	Edgar Link	pending
prestige-amendmentno7tot034.jpg	Edgar Link	pending
prestige-amendmentno7tot035.jpg	Edgar Link	pending
prestige-amendmentno7tot036.jpg	Edgar Link	pending
prestige-amendmentno7tot037.jpg	Edgar Link	pending
prestige-amendmentno7tot038.jpg	Edgar Link	pending
prestige-amendmentno7tot039.jpg	Edgar Link	pending
prestige-amendmentno7tot040.jpg	Edgar Link	pending
pbh-20230630_def.xml	Edgar Link	unprocessable
pbh-20230630_lab.xml	Edgar Link	unprocessable
pbh-20230630_pre.xml	Edgar Link	unprocessable
pbh-20230630_htm.xml	Edgar Link	completed
prestige-amendmentno7tot041.jpg	Edgar Link	pending
prestige-amendmentno7tot042.jpg	Edgar Link	pending
prestige-amendmentno7tot043.jpg	Edgar Link	pending
prestige-amendmentno7tot044.jpg	Edgar Link	pending
prestige-amendmentno7tot045.jpg	Edgar Link	pending
prestige-amendmentno7tot046.jpg	Edgar Link	pending
prestige-amendmentno7tot047.jpg	Edgar Link	pending
prestige-amendmentno7tot048.jpg	Edgar Link	pending
prestige-amendmentno7tot049.jpg	Edgar Link	pending
prestige-amendmentno7tot050.jpg	Edgar Link	pending
prestige-amendmentno7tot051.jpg	Edgar Link	pending
prestige-amendmentno7tot052.jpg	Edgar Link	pending
prestige-amendmentno7tot053.jpg	Edgar Link	pending
prestige-amendmentno7tot054.jpg	Edgar Link	pending
prestige-amendmentno7tot055.jpg	Edgar Link	pending
prestige-amendmentno7tot056.jpg	Edgar Link	pending
prestige-amendmentno7tot057.jpg	Edgar Link	pending
prestige-amendmentno7tot058.jpg	Edgar Link	pending
prestige-amendmentno7tot059.jpg	Edgar Link	pending
prestige-amendmentno7tot060.jpg	Edgar Link	pending
prestige-amendmentno7tot061.jpg	Edgar Link	pending
prestige-amendmentno7tot062.jpg	Edgar Link	pending
prestige-amendmentno7tot063.jpg	Edgar Link	pending
prestige-amendmentno7tot064.jpg	Edgar Link	pending
prestige-amendmentno7tot065.jpg	Edgar Link	pending
prestige-amendmentno7tot066.jpg	Edgar Link	pending
prestige-amendmentno7tot067.jpg	Edgar Link	pending
prestige-amendmentno7tot068.jpg	Edgar Link	pending
prestige-amendmentno7tot069.jpg	Edgar Link	pending
prestige-amendmentno7tot070.jpg	Edgar Link	pending
prestige-amendmentno7tot071.jpg	Edgar Link	pending
prestige-amendmentno7tot072.jpg	Edgar Link	pending
prestige-amendmentno7tot073.jpg	Edgar Link	pending
prestige-amendmentno7tot074.jpg	Edgar Link	pending
prestige-amendmentno7tot075.jpg	Edgar Link	pending
prestige-amendmentno7tot076.jpg	Edgar Link	pending
prestige-amendmentno7tot077.jpg	Edgar Link	pending
prestige-amendmentno7tot078.jpg	Edgar Link	pending
prestige-amendmentno7tot079.jpg	Edgar Link	pending
prestige-amendmentno7tot080.jpg	Edgar Link	pending
prestige-amendmentno7tot081.jpg	Edgar Link	pending
prestige-amendmentno7tot082.jpg	Edgar Link	pending
prestige-amendmentno7tot083.jpg	Edgar Link	pending
prestige-amendmentno7tot084.jpg	Edgar Link	pending
prestige-amendmentno7tot085.jpg	Edgar Link	pending
prestige-amendmentno7tot086.jpg	Edgar Link	pending
prestige-amendmentno7tot087.jpg	Edgar Link	pending
prestige-amendmentno7tot088.jpg	Edgar Link	pending
prestige-amendmentno7tot089.jpg	Edgar Link	pending
prestige-amendmentno7tot090.jpg	Edgar Link	pending
prestige-amendmentno7tot091.jpg	Edgar Link	pending
prestige-amendmentno7tot092.jpg	Edgar Link	pending
prestige-amendmentno7tot093.jpg	Edgar Link	pending
prestige-amendmentno7tot094.jpg	Edgar Link	pending
prestige-amendmentno7tot095.jpg	Edgar Link	pending
prestige-amendmentno7tot096.jpg	Edgar Link	pending
prestige-amendmentno7tot097.jpg	Edgar Link	pending
prestige-amendmentno7tot098.jpg	Edgar Link	pending
prestige-amendmentno7tot099.jpg	Edgar Link	pending
prestige-amendmentno7tot100.jpg	Edgar Link	pending
prestige-amendmentno7tot101.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pbh-20230630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBH
Prestige Consumer Healthcare Inc. Stock $pbh

2023 Q3 Form 10-Q Financial Statement

#000129594723000026 Filed on August 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBH Prestige Consumer Healthcare Inc. Stock $pbh

2023 Q3 Form 10-Q Financial Statement

#000129594723000026 Filed on August 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBH
Prestige Consumer Healthcare Inc. Stock $pbh